Post by
overnout on Nov 18, 2021 5:04pm
Very Soldi 3rd Q Results
BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2021. Key highlights include: Third quarter (Q3) 2021 Net Revenues of $6,690,419 increased by 16% versus Q3 2020 Year-to-date (YTD) 2021 Net Revenues of $21,399,562 increased by 29% versus YTD 2020 Canadian Pharmaceutical Net Revenues in Q3 2021 of $6,409,809 increased by 17% versus Q3 2020 YTD 2021 Canadian Pharmaceutical Net Revenues of $19,313,894 increased by 22% versus YTD 2020 Q3 2021 International Pharmaceutical Net Revenues of $Nil as compared to $6,306 in Q3 2020 YTD 2021 International Pharmaceutical Net Revenues of $1,305,317 increased by 675% versus YTD 2020 Q3 2021 EBITDA1 of $2,293,713 increased by 64% versus Q3 2020 YTD 2021 EBITDA1 of $6,144,581 increased by 38% versus YTD 2020 Q3 2021 Net Income After Taxes (NIAT) of $1,721,320 increased by 80% versus Q3 2020 YTD 2021 NIAT of $4,403,762 increased by 41% versus YTD 2020 Q3 2021 NIAT percentage to Net Revenues of 26% compares to 17% in Q3 2020 YTD 2021 NIAT percentage to Net Revenues of 21% compares to 19% in YTD 2020 Q3 2021 Fully Diluted EPS of $0.13 was $0.06 higher than Q3 2020 Fully Diluted EPS of $0.07 YTD 2021 Fully Diluted EPS of $0.34 was $0.10 higher than YTD 2020 Fully Diluted EPS of $0.24 Fully Diluted EPS for the Trailing Twelve Months ended September 30, 2021 was $0.39 as compared to $0.32 for the Trailing Twelve Months ended September 30, 2020 As at September 30, 2021, the Company had cash, cash equivalents, and short-term investments totalling $27,101,933, a 6% increase as compared to $25,577,706 as at December 31, 2020 Total Shareholders’ Equity increased by 13% to $30,332,390 at September 30, 2021 from $26,795,956 at December 31, 2020 Return on Equity for the Trailing Twelve Months ended September 30, 2021 was 18% as compared to 17% for the Trailing Twelve Months ended September 30, 2020 During YTD 2021, repurchased and cancelled a total of 79,700 common shares under a Normal Course Issuer Bid (NCIB) “